Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus
NCT ID: NCT00690638
Last Updated: 2010-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
480 participants
INTERVENTIONAL
2008-07-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
NCT00865592
Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
NCT01101945
Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
NCT00998686
Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment
NCT00958269
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
NCT01089790
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Placebo
Placebo
Placebo
2
PHX1149T 200 mg
PHX1149T
200 mg
3
PHX1149T 400 mg
PHX1149T
400 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PHX1149T
200 mg
PHX1149T
400 mg
Placebo
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI 25 to 48 kg/m2, inclusive
* HbA1c 7.0% - 10.0%, inclusive
* Age 18 to 75 years, inclusive
Exclusion Criteria
* Type 1 diabetes mellitus
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forest Laboratories
INDUSTRY
Phenomix
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Phenomix Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Norwalk, California, United States
Orange, California, United States
Santa Ana, California, United States
Daytona Beach, Florida, United States
Kissimmee, Florida, United States
Atlanta, Georgia, United States
Honolulu, Hawaii, United States
Brockton, Massachusetts, United States
St Louis, Missouri, United States
Cincinnati, Ohio, United States
El Paso, Texas, United States
San Antonio, Texas, United States
Norfolk, Virginia, United States
Caba, Buenos Aires, Argentina
La Plata, Buenos Aires, Argentina
Lanús, Buenos Aires, Argentina
Paraná, Entre Ríos Province, Argentina
Salta, Salta Province, Argentina
Rosario, Santa Fe Province, Argentina
Corrientes, , Argentina
Hyderabad, Andhara Pradesh, India
Bangalore, Karnataka, India
Kalaburagi, Karnataka, India
Mumbai, Maharashtra, India
Nagpur, Maharashtra, India
Nashik, Maharashtra, India
Navi Mumbai, Maharashtra, India
Pune, Maharashtra, India
Chennai, Tamil Nadu, India
Kelantan, , Malaysia
Kuala Lumpur, , Malaysia
Perak, , Malaysia
Sarawak, , Malaysia
Arequipa, Arequipa, Peru
Chiclayo-Lambayeque, Chiclayo, Peru
Lima Cercado, Lima region, Peru
Lince, Lima region, Peru
San Miguel, Lima region, Peru
San Isisdro, Lima, Peru
Manila, NCR, Philippines
Quezon City, NCR, Philippines
San Juan City, NCR, Philippines
Cebu City, VII, Philippines
Brasov, Brașov County, Romania
Jud. Brasov, Brașov County, Romania
Sector 1, Bucharest, Romania
Sector 2, Bucharest, Romania
Galati, Galați County, Romania
Ploieşti, Ploiesti, Romania
Sibiu, Sibiu County, Romania
Ratchatavi, Bangkok, Thailand
Muang, Changwat Khon Kaen, Thailand
Simferopol, Crimean Autonomy Republic, Ukraine
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
Kharkiv, Kharkivs’ka Oblast’, Ukraine
2A Postysheva Pr., Kharkov, Ukraine
Kiev, Kyiv City, Ukraine
Kyiv, Kyiv Oblast, Ukraine
Lviv, Lviv Oblast, Ukraine
Poltava, Poltava Oblast, Ukraine
Vinnytsa, Vinnytsa, Ukraine
Zaporizhzhia, Zaporizhzhia Oblast, Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT 2008-002614-22
Identifier Type: -
Identifier Source: secondary_id
PHX1149-PROT301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.